CL2016002318A1 - Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. - Google Patents
Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.Info
- Publication number
- CL2016002318A1 CL2016002318A1 CL2016002318A CL2016002318A CL2016002318A1 CL 2016002318 A1 CL2016002318 A1 CL 2016002318A1 CL 2016002318 A CL2016002318 A CL 2016002318A CL 2016002318 A CL2016002318 A CL 2016002318A CL 2016002318 A1 CL2016002318 A1 CL 2016002318A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical composition
- liquid carrier
- oral dosage
- dosage form
- solution
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 6
- 239000007788 liquid Substances 0.000 title abstract 4
- 239000006186 oral dosage form Substances 0.000 title abstract 3
- 150000001298 alcohols Chemical class 0.000 title abstract 2
- 229960002639 sildenafil citrate Drugs 0.000 title abstract 2
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 abstract 4
- 229960003310 sildenafil Drugs 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 239000006193 liquid solution Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01Q—ANTENNAS, i.e. RADIO AERIALS
- H01Q5/00—Arrangements for simultaneous operation of antennas on two or more different wavebands, e.g. dual-band or multi-band arrangements
- H01Q5/50—Feeding or matching arrangements for broad-band or multi-band operation
- H01Q5/55—Feeding or matching arrangements for broad-band or multi-band operation for horn or waveguide antennas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01Q—ANTENNAS, i.e. RADIO AERIALS
- H01Q1/00—Details of, or arrangements associated with, antennas
- H01Q1/27—Adaptation for use in or on movable bodies
- H01Q1/28—Adaptation for use in or on aircraft, missiles, satellites, or balloons
- H01Q1/288—Satellite antennas
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01Q—ANTENNAS, i.e. RADIO AERIALS
- H01Q1/00—Details of, or arrangements associated with, antennas
- H01Q1/36—Structural form of radiating elements, e.g. cone, spiral, umbrella; Particular materials used therewith
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Astronomy & Astrophysics (AREA)
- Remote Sensing (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Aviation & Aerospace Engineering (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
El objetivo abordado en la presente solicitud corresponde a la necesidad de proporcionar una composición farmacéutica que posea una biodisponibilidad incrementada de sildenafil, de modo de proporcionar en menos tiempo el mismo efecto terapéutico comparado con el proporcionado por una tableta existente en el estado de la técnica, además que permita reducir la dosis efectiva de sildenafil para mitigar sus efectos secundarios no deseados. Como solución se propone una composición farmacéutica en forma de solución líquida que comprende: (a) un portador líquido que comprende agua y entre 20% y 95% de uno o más alcoholes; y (b) citrato de sildenafil disuelto en dicho portador líquido a una concentración entre 7mg/ml y 125 mg/ml. Además se divulga una forma farmacéutica oral y bucal que comprenden a la composición farmacéutica, Kits que comprenden a la composición farmacéutica y métodos para preparar a la composición farmacéutica en forma de solución.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461955299P | 2014-03-19 | 2014-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016002318A1 true CL2016002318A1 (es) | 2017-03-24 |
Family
ID=54145440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016002318A CL2016002318A1 (es) | 2014-03-19 | 2016-09-14 | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9968609B2 (es) |
| EP (2) | EP3119201B1 (es) |
| JP (1) | JP6744821B2 (es) |
| KR (1) | KR20160137584A (es) |
| CN (1) | CN106132204B (es) |
| AU (2) | AU2015233006B2 (es) |
| CA (1) | CA2942628C (es) |
| CL (1) | CL2016002318A1 (es) |
| CY (1) | CY1120187T1 (es) |
| DK (1) | DK3119201T3 (es) |
| EA (1) | EA032819B1 (es) |
| ES (1) | ES2668915T3 (es) |
| HR (1) | HRP20180773T1 (es) |
| HU (1) | HUE038431T2 (es) |
| IL (1) | IL247840B (es) |
| LT (1) | LT3119201T (es) |
| MX (1) | MX371276B (es) |
| NO (1) | NO2723977T3 (es) |
| PL (1) | PL3119201T3 (es) |
| PT (1) | PT3119201T (es) |
| RS (1) | RS57206B1 (es) |
| SG (2) | SG10201808038TA (es) |
| SI (1) | SI3119201T1 (es) |
| SM (1) | SMT201800268T1 (es) |
| WO (1) | WO2015140748A2 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2723977T3 (es) | 2014-03-19 | 2018-03-10 | ||
| JP6902372B2 (ja) * | 2017-02-28 | 2021-07-14 | ヱスビー食品株式会社 | 苦味抑制用組成物 |
| EP3731870B1 (en) | 2017-12-26 | 2025-11-12 | Liqmeds Limited | Liquid oral formulations for pde v inhibitors |
| WO2020212931A1 (en) * | 2019-04-18 | 2020-10-22 | Vigorous Solutions Ltd. | Liquid sildenafil citrate compositions |
| US20220387433A1 (en) * | 2019-11-12 | 2022-12-08 | American Regent, Inc. | Type v phosphodiesterase inhibitor compositions, methods of making them and methods of using them in preventing or treating elevated pulmonary vascular pressure or pulmonary hemorrhages |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1065415C (zh) * | 1993-02-05 | 2001-05-09 | 花王株式会社 | 蛋白质和类脂复合体用于改善味觉的用途 |
| US5785984A (en) * | 1993-02-05 | 1998-07-28 | Kao Corporation | Taste-modifying method and bitterness-decreasing method |
| US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| TWI223598B (en) | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
| US6531114B1 (en) | 1999-04-06 | 2003-03-11 | Wm. Wrigley Jr. Company | Sildenafil citrate chewing gum formulations and methods of using the same |
| US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| TWI224966B (en) | 1999-11-02 | 2004-12-11 | Pfizer | Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient |
| EP1237538A2 (en) * | 1999-11-18 | 2002-09-11 | Natco Pharma Limited | An improved pharmaceutical composition for treating male erectile dysfunction |
| EP1255566A2 (en) | 2000-02-04 | 2002-11-13 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| AU2001273545A1 (en) | 2000-07-19 | 2002-01-30 | Lavipharm Laboratories, Inc. | Sildenafil citrate solid dispersions having high water solubility |
| US20030216407A1 (en) | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
| US7611728B2 (en) | 2003-09-05 | 2009-11-03 | Supernus Pharmaceuticals, Inc. | Osmotic delivery of therapeutic compounds by solubility enhancement |
| WO2005046632A2 (en) | 2003-11-17 | 2005-05-26 | Patus Ltd. | Compositions effective in altering the perception of malodor |
| ATE387203T1 (de) | 2004-01-05 | 2008-03-15 | Teva Pharma | Prozesse zur herstellung von sildenafil-base und zitratsalz |
| CN1925860A (zh) * | 2004-01-05 | 2007-03-07 | 特瓦制药工业有限公司 | 制备西地那非碱及其柠檬酸盐的方法 |
| US7727565B2 (en) | 2004-08-25 | 2010-06-01 | Cadbury Adams Usa Llc | Liquid-filled chewing gum composition |
| KR20130122988A (ko) | 2005-03-14 | 2013-11-11 | 와이어쓰 엘엘씨 | 티게사이클린 조성물 및 이의 제조방법 |
| US7556487B2 (en) | 2006-03-29 | 2009-07-07 | Intergum Gida Sinayi ve Ticaret A.S. | Apparatus for making center-filled chewing gum pieces |
| FR2906140B1 (fr) * | 2006-09-22 | 2008-12-05 | Philippe Perovitch | Forme galenique pour l'administration par voie trans-muqueuse de principes actifs |
| DE502008002360D1 (de) | 2007-06-19 | 2011-03-03 | Symrise Ag | Aromakomposition zum Verringern oder Unterdrücken von unerwünschtem bitteren und adstringierenden Eindruck |
| EP2072044A1 (en) * | 2007-12-19 | 2009-06-24 | Abbott GmbH & Co. KG | Pharmaceutical dosage form comprising a liquid or flowable core composition |
| WO2009125415A1 (en) | 2008-04-07 | 2009-10-15 | Hetero Research Foundation | Amorphous form of sildenafil citrate |
| FR2939321B1 (fr) | 2008-12-05 | 2011-08-26 | Philippe Perovitch | Dispositif de conditionnement et d'administration de principes actifs en solution hydro-alcoolique. |
| US8642270B2 (en) | 2009-02-09 | 2014-02-04 | Vm Institute Of Research | Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer |
| DE102010049708A1 (de) * | 2010-10-28 | 2012-05-03 | Hexal Ag | Orale pharmazeutische Filmformulierung für bitter schmeckende Arzneistoffe |
| CA2858364C (en) | 2011-12-05 | 2018-07-24 | Foye Opawale | Oral spray formulations and methods for administration of sildenafil |
| GB2497933B (en) | 2011-12-21 | 2014-12-24 | Londonpharma Ltd | Drug delivery technology |
| CN111012914A (zh) * | 2012-01-18 | 2020-04-17 | 苏州泰飞尔医药有限公司 | 治疗肺部疾病的高穿透力前药组合物和医药组合物 |
| WO2014151729A1 (en) | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| NO2723977T3 (es) | 2014-03-19 | 2018-03-10 |
-
2012
- 2012-04-16 NO NO12802846A patent/NO2723977T3/no unknown
-
2015
- 2015-03-19 WO PCT/IB2015/052014 patent/WO2015140748A2/en not_active Ceased
- 2015-03-19 EP EP15764710.8A patent/EP3119201B1/en active Active
- 2015-03-19 CN CN201580013951.5A patent/CN106132204B/zh not_active Expired - Fee Related
- 2015-03-19 RS RS20180533A patent/RS57206B1/sr unknown
- 2015-03-19 CA CA2942628A patent/CA2942628C/en active Active
- 2015-03-19 KR KR1020167029017A patent/KR20160137584A/ko not_active Ceased
- 2015-03-19 LT LTEP15764710.8T patent/LT3119201T/lt unknown
- 2015-03-19 AU AU2015233006A patent/AU2015233006B2/en not_active Ceased
- 2015-03-19 EA EA201691871A patent/EA032819B1/ru unknown
- 2015-03-19 SG SG10201808038TA patent/SG10201808038TA/en unknown
- 2015-03-19 ES ES15764710.8T patent/ES2668915T3/es active Active
- 2015-03-19 SM SM20180268T patent/SMT201800268T1/it unknown
- 2015-03-19 JP JP2016558141A patent/JP6744821B2/ja not_active Expired - Fee Related
- 2015-03-19 MX MX2016012154A patent/MX371276B/es active IP Right Grant
- 2015-03-19 PL PL15764710T patent/PL3119201T3/pl unknown
- 2015-03-19 HU HUE15764710A patent/HUE038431T2/hu unknown
- 2015-03-19 HR HRP20180773TT patent/HRP20180773T1/hr unknown
- 2015-03-19 SG SG11201607507VA patent/SG11201607507VA/en unknown
- 2015-03-19 PT PT157647108T patent/PT3119201T/pt unknown
- 2015-03-19 DK DK15764710.8T patent/DK3119201T3/en active
- 2015-03-19 EP EP18161634.3A patent/EP3372083A1/en not_active Withdrawn
- 2015-03-19 SI SI201530249T patent/SI3119201T1/en unknown
-
2016
- 2016-09-14 CL CL2016002318A patent/CL2016002318A1/es unknown
- 2016-09-15 US US15/265,897 patent/US9968609B2/en not_active Expired - Fee Related
- 2016-09-15 IL IL247840A patent/IL247840B/en active IP Right Grant
-
2018
- 2018-04-12 US US15/951,197 patent/US10211534B2/en active Active
- 2018-05-03 CY CY20181100459T patent/CY1120187T1/el unknown
- 2018-10-16 AU AU2018250378A patent/AU2018250378B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010140A (es) | Nuevos metodos. | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
| MX2020007023A (es) | Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| NI201600058A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| PE20140051A1 (es) | Metodos y productos de farmaco para tratar enfermedad de alzheimer | |
| GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| MA38399B2 (fr) | Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique | |
| GT201500053A (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. | |
| MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
| AR091351A1 (es) | Formulaciones de bromocriptina, metodo para mejorar el control glucemico y metodo para la fabricacion | |
| MX2015013784A (es) | C. novyi para el tratamiento de tumores solidos en humanos. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| CL2015003468A1 (es) | Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d. | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| PE20151300A1 (es) | Composicion antifungica topica para el tratamiento de onicomicosis | |
| AR088845A1 (es) | Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel | |
| AR107298A1 (es) | Método de purificación | |
| AR100153A1 (es) | Medicamento | |
| RU2014106575A (ru) | Способ профилактики кровотечения при миомэктомии |